This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Glenn E. Mathisen, MD
Infectious Disease Division Los Angeles County Olive View Medical Center Sylmar, CA 91342

Allen D. Allen, PhD
Biomedical Sciences Division Algorithms Inc Northridge, CA 91325

Arch Dermatol. 1990;126(6):833-834.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Kaposi's sarcoma (KS) is a neoplasm characterized by a proliferation of fibroblastic and microvascular elements with abnormal endothelial cells, extravasated erythrocytes, and spindle-shaped cell infiltration. Kaposi's sarcoma may be systemic with many foci in the mucous membranes, lymph nodes, or visceral organs. In current epidemiology, however, a virulent cutaneous form found on the extremities, trunk, neck, head, or in the oral cavity is a sign of acquired immunodeficiency syndrome (AIDS) in patients infected with the human immunodeficiency virus (HIV).^1,2

Treatment for KS-AIDS has included chemotherapy, radiation therapy, antiretroviral agents, and immunomodulators in patients with indolent disease.^3,4 Because of severely depressed cell-mediated immunity, KS-AIDS patients have a poor tolerance for the myelosuppressive effects of standard antineoplastic agents.⁵ Recombinant interferon alfa has been the most thoroughly studied of the nonsuppressive immunomodulators, and is most likely to be beneficial in the absence of systemic disease and opportunistic . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?